getITD for FLT3-ITD-based MRD monitoring in AML

Leukemia. 2019 Oct;33(10):2535-2539. doi: 10.1038/s41375-019-0483-z. Epub 2019 May 14.

Authors

Affiliations

¹ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
² Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.
³ Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany. lars.bullinger@charite.de.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Base Sequence
Cell Line, Tumor
Female
Gene Frequency / genetics
HL-60 Cells
Humans
Leukemia, Myeloid, Acute / genetics
Male
Mutation / genetics
Neoplasm, Residual / genetics*
fms-Like Tyrosine Kinase 3 / genetics*

Substances

FLT3 protein, human
fms-Like Tyrosine Kinase 3